Bolivia Samples for Class I Devices: Rules and Warehouse Verification
Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20
1. Key takeaways
Section 2.6 of the Manual provides that only Class I devices require sample submission; devices of other risk levels are not accompanied by samples, but AGEMED may verify the products at the company’s warehouse at any time. GRZAN’s assessment is that this rule converts the compliance obligation from sending one sample into maintaining a warehouse condition that is verifiable on demand. For importers, this means the warehouse must hold physical stock consistent with the registered information over the long term, and the on-site condition of the lot numbers, the labels and the Spanish instructions must remain consistent with the dossier. A registration that looks complete on paper can still fail a field check if the goods on the shelf do not match the approved documentation. Companies should therefore treat warehouse readiness as part of the registration project itself, not as a post-approval logistics matter, and align storage practices with the registered document set from the first shipment onward. Where several importers or warehouses are used, the standard should be applied uniformly, since a check at any one of them reflects on the registration. The practical consequence is that warehouse discipline becomes part of regulatory compliance, and the storage practices of the importer should be audited with the same seriousness as the dossier itself.
2. Legal basis
| Regulation | Reference number | Publication date | Provision |
|---|---|---|---|
| Manual para Registro Sanitario de Dispositivos Médicos | Resolución Ministerial N° 010 | Current version as published on the AGEMED website | Section 2.6 |
| Manual para Registro Sanitario de Dispositivos Médicos | Resolución Ministerial N° 010 | Current version as published on the AGEMED website | Section 1.7 |
| Manual para Registro Sanitario de Dispositivos Médicos | Resolución Ministerial N° 010 | Current version as published on the AGEMED website | Section 2.5 |
| Decreto Supremo (establishing AGEMED) | Decreto Supremo N° 2905 | September 21, 2016 | Article 2 |
3. Expert insights
Insight one: samples are required only for Class I, which is one of the few advantages that comes with the lowest classification. The higher the risk level, the stricter the documentation requirements, yet the sample requirement appears only at the lowest level. This counter-intuitive design shows that the role of samples in Bolivia is to verify the consistency of simple products, where a physical item is the fastest way to confirm what the file describes, while the verification of high-risk products is entrusted to the technical documentation and to warehouse inspection. Companies should read the rule as a signal about how AGEMED verifies, not merely as an administrative exemption to be enjoyed. For Class I submissions, the sample should be prepared with the same label and instruction set that will be commercialized, since the sample becomes the reference point for later comparison. The sample and its accompanying documents should be archived so that the reference remains available through the life of the registration. This reading also explains why the rule does not scale with risk: the higher the risk, the richer the file, and the less a single unit adds.
Insight two: warehouse verification can happen at any time, with no notice period. The wording of Section 2.6 does not provide for advance notification. This requires importers to maintain warehouse compliance as a normal, ongoing state rather than as a condition prepared for an announced visit. GRZAN includes this point as a field item in importer due diligence: look at the warehouse zoning, look at the lot number ledger, and check whether the Spanish instructions travel with the goods. A warehouse that passes this walk-through can absorb an unannounced AGEMED visit; one that cannot will generate findings that reflect back on the registration holder. The lot number ledger should allow any lot on the shelf to be traced to its import document within minutes, because that is the standard an unannounced visit effectively demands. Photographic records of the storage layout, kept current, shorten preparation for any visit and help new staff maintain the standard.
Insight three: AGEMED verification and SEDES local inspection are two separate lines. AGEMED carries out its work in coordination with the departmental health services (SEDES) of the 9 departments of the country. A warehouse may face both types of inspection, and the preparation standard should therefore be the union of the two sets of expectations, covering registration consistency on one side and local storage and distribution conditions on the other. Importers should ask which SEDES has jurisdiction over their location and track its inspection practice as part of routine compliance management. Corrective actions from either line of inspection should be shared across both, because findings from one often predict findings from the other.
4. Practical recommendations
- Add one on-site warehouse audit to importer due diligence, focusing on the lot number ledger and the documents that accompany the goods during distribution.
- Require the importer to hold physical stock consistent with the dossier on a long-term basis, so that there is always something verifiable after registration rather than an empty shelf, with stock levels reviewed against the registration scope at defined intervals.
- Write the obligation to cooperate with AGEMED warehouse verification into the distribution agreement, defining the importer’s cooperation duties and the consequences of breach.
- Train warehouse staff on the registered label and instruction set, so that the on-site condition stays aligned with the dossier through personnel changes.
5. Verification checklist
- □ The product risk level has been determined, and whether samples must be submitted follows from it
- □ If Class I, samples have been prepared in accordance with Section 2.6
- □ The importer’s warehouse holds physical stock consistent with the dossier on a long-term basis
- □ The on-site labels, lot numbers and Spanish instructions match the dossier
- □ The distribution agreement contains a clause on the obligation to cooperate with warehouse verification
Regulatory information verified as of October 29, 2026.
GRZAN provides registration support in Bolivia for manufacturers, importers and authorized representatives, covering sample preparation, warehouse readiness review, importer due diligence and regulatory correspondence. For assistance with Section 2.6 requirements and the full registration process, contact info@grzanglobal.com.
Disclaimer
Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.
About GRZAN
GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.
GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.
Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.
What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.
Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.
Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.
Take your devices global with GRZAN
We work with manufacturers worldwide to open new markets with a clear regulatory pathway.
Contact us